A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
The main goals of this study are to further determine whether the study drug donanemab is
 safe and effective in participants with Alzheimer's disease and to validate video scale
 assessments.
Inclusion Criteria:

 -  Participated in a double-blind treatment period of a sponsor-approved originating
 donanemab trial, for example the TRAILBLAZER-ALZ study.

 -  Have a study partner

 -  Stable symptomatic Alzheimer's Disease (AD) medications and other medication that may
 impact cognition for at least 30 days prior to randomization into Part A

 Exclusion Criteria:

 -  Current serious or unstable illnesses including cardiovascular, hepatic, renal,
 gastroenterologic, respiratory, endocrinologic, neurologic (other than AD),
 psychiatric, immunologic, or hematologic disease and other conditions that, in the
 investigator's opinion, could interfere with outcome assessments or the analyses in
 this study.

 -  Have received treatment with a passive anti-amyloid immunotherapy after completion of
 originating donanemab study or received active immunization against Aβ in any other
 study.

 -  Poor venous access

 -  Contraindication to PET or MRI imaging